3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
3
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
251
Lymphoma
241
Precursor Cell Lymphoblastic Leukemia-Lymphoma
192
Leukemia
178
Lymphoma, Large B-Cell, Diffuse
167
Multiple Myeloma
166
Lymphoma, Non-Hodgkin
155
Leukemia, Lymphocytic, Chronic, B-Cell
146
Leukemia, Myeloid, Acute
136
Myelodysplastic Syndromes
116
Hodgkin Disease
115
Lymphoma, Follicular
113
Burkitt Lymphoma
108
Lymphoma, Mantle-Cell
104
Lymphoma, B-Cell, Marginal Zone
76
Lymphoma, Large-Cell, Immunoblastic
64
Neoplasms, Plasma Cell
59
Recurrence
58
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
57
Myeloproliferative Disorders
53
Neoplasms
49
Leukemia, Myeloid, Chronic-Phase
49
Triple Negative Breast Neoplasms
47
Leukemia, Myeloid, Accelerated Phase
47
Melanoma
46
Leukemia, Myelomonocytic, Chronic
46
Dendritic Cell Sarcoma, Interdigitating
46
Waldenstrom Macroglobulinemia
42
Hematologic Neoplasms
41
Congenital Abnormalities
39
Interventions
Oxaliplatin
146
Fluorouracil
137
Capecitabine
121
Leucovorin
106
Irinotecan
85
Radiotherapy
66
Bevacizumab
64
Cetuximab
46
Folfox protocol
27
Surgical Procedures, Operative
23
Radiation
23
Drug Therapy
22
Panitumumab
19
XELOX
18
Chemotherapy, Adjuvant
15
Neoadjuvant Therapy
14
Radiotherapy, Intensity-Modulated
13
Chemoradiotherapy
13
Magnetic Resonance Spectroscopy
11
regorafenib
10
Nivolumab
10
Floxuridine
10
sintilimab
8
raltitrexed
8
Specimen Handling
8
IFL protocol
8
Celecoxib
8
Biopsy
8
trifluridine tipiracil drug combination
7
tislelizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rectal Neoplasms
×
Cyclophosphamide
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts